This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
CADTH. Long term use of clopidogrel for patients with stents or acute coronary syndrome: a review of clinical and cost-effectiveness and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary with Critical Appraisal. 2013
There appears to be uncertainty regarding the effectiveness of use of clopidogrel beyond one year. Results from the included studies were inconsistent and the majority of the studies were retrospective. In the evidence based guidelines there were no strong recommendations for use of clopidogrel beyond one year.
Subject indexing assigned by CRD
Acute Coronary Syndromes; Anticoagulants; Platelet Aggregation Inhibitors; Stents; Ticlopidine
Country of organisation
An English language summary is available.
Address for correspondence
Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, Ottawa, Ontario Canada, K1S 5S8 Email: firstname.lastname@example.org
Date abstract record published